Suchergebnisse - "Zenz, Thorsten"

PubPharm (10)

1

New lessons learned in T-PLL : results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance

enthalten in: Leukemia & lymphoma | 2019

von Pflug, N. | Cramer, P. | Robrecht, S. | +15

2

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab : results from the CLL2H trial of the GCLLSG

enthalten in: Blood | 2013

von Schnaiter, A. | Paschka, P. | Rossi, M. | +13

3

Risk categories and refractory CLL in the era of chemoimmunotherapy

enthalten in: Blood | 2012

von Zenz, T. | Gribben, J. | Hallek, M. | +3

4

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia : a multivariate analysis from the randomized GCLLSG CLL8 trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2012

von Böttcher, S. | Ritgen, M. | Fischer, K. | +13

5

Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2012

von Dietrich, S. | Krämer, O. | Hahn, E. | +10

6

TP53 mutation and survival in chronic lymphocytic leukemia

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2010

von Zenz, T. | Eichhorst, B. | Busch, R. | +11

CommentIn: J Clin Oncol. 2012 Feb 10;30(5):469-70. - PMID 22184387

7

Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology : aberrant p53 expression predicts response and survival

enthalten in: Leukemia & lymphoma | 2009

von Zenz, T. | Stilgenbauer, S.

CommentOn: Leuk Lymphoma. 2009 Oct;50(10):1597-605. - PMID 19863337

8

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL) : dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

enthalten in: Blood | 2009

von Zenz, T. | Häbe, S. | Denzel, T. | +10

9

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia : clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2009

von Stilgenbauer, S. | Zenz, T. | Winkler, D. | +17

10

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55 : results of a phase I-II study

enthalten in: British journal of haematology | 2005

von Ringhoffer, M. | Blumstein, N. | Neumaier, B. | +12

1
[1]